On September 29, Kodiak Sciences Inc. declined 7.83% overnight, trading at $84.3 per share with turnover of approximately $460,400. The retreat follows a dramatic 146.43% surge during the prior regular session, when the company announced its two experimental eye drugs, Zenkuda and tabirafusp-ted, both met primary endpoints in Phase 3 studies for wet age-related macular degeneration.

Both treatments achieved non-inferiority in vision gains compared with aflibercept during the first year, with 54% of patients maintaining a six-month dosing interval. The company plans to submit Zenkuda data from five positive Phase 3 studies to regulatory authorities in Q4, covering wet AMD, diabetic retinopathy, and macular edema following retinal vein occlusion. Prior to the data readout, UBS had maintained a buy rating with an $80 price target, a level the stock has now surpassed. The overnight pullback occurred on notably thin volume relative to the prior session's $1.57 billion in turnover, suggesting partial profit-taking following the outsized move.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)